These solutions leverage the power of Illumina's leading NovaSeq X series platform and will enable researchers to derive breakthrough insights around the drivers of disease. The company will also ...
As Illumina transitions to its new NovaSeq X platform and implements cost-cutting measures, investors and analysts are closely watching to see if the company can maintain its market leadership and ...
Illumina is raising the curtain on its upcoming ... The company said its spatial technology will run on its current NextSeq and NovaSeq hardware through a new multimodal software platform, with ...
The spatial solution surpasses industry standards for scale and accuracy, and is compatible with Illumina NextSeq and NovaSeq sequencers, thereby materially reducing the cost of running large ...
Illumina will seek to cut $100 million in expenses ... multimodal software platform that runs on its current NextSeq and NovaSeq hardware. The company is also developing what it describes as ...
Further innovation, like the NovaSeq, continued to push down these costs, and Illumina expects its new NovaSeq X Series to enable the $100 genome, which could greatly increase the accessibility of ...
The combination of Illumina's Single Cell Prep, NovaSeq X Plus platform, 25B flow cell and DRAGEN analysis software creates a seamless end-to-end workflow enabling the high-throughput processing of ...
Illumina faces significant challenges from China's "unreliable entity list" and competition from Roche's new SBX technology, impacting its growth prospects. Despite a 37% stock decline since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback